Document is current
Any future updates will be listed below
-
Authors
Yu, Guoying
Tzouvelekis, Argyris
Wang, Rong
Herazo-Maya, Jose D
Ibarra, Gabriel H
Srivastava, Anup
de Castro, Joao Pedro Werneck
DeIuliis, Giuseppe
Ahangari, Farida
Woolard, Tony
Aurelien, Nachelle
Arrojo e Drigo, Rafael
Gan, Ye
Graham, Morven
Liu, Xinran
Homer, Robert J
Scanlan, Thomas S
Mannam, Praveen
Lee, Patty J
Herzog, Erica L
Bianco, Antonio C
Kaminski, Naftali https://orcid.org/0000-0001-5917-4601
- License Information
-
More Information
Article History
Received: 23 November 2015
Accepted: 23 October 2017
First Online: 4 December 2017
Competing interests
: A.T., G.Y. and N.K. are inventors on a pending patent with the US Patent and Trademark Office on use of thyroid hormone as an antifibrotic agent entitled “Novel methods of treating or preventing fibrotic lung diseases,” OCR 6368-047162-7029P1 (00219). N.K. consulted for Biogen Idec, Boehringer Ingelheim, Numedii, MMI and Pliant and has an ongoing collaboration with MiRagen, all outside the subject matter of the submitted work. E.L.H. consulted for Boehringer Ingelheim and held grant funding from Sanofi and Promedior, all outside the subject matter of the submitted work. All other authors declare no competing interests.
